<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835013</url>
  </required_header>
  <id_info>
    <org_study_id>COCOA</org_study_id>
    <secondary_id>18/EM/0417</secondary_id>
    <secondary_id>250402</secondary_id>
    <nct_id>NCT03835013</nct_id>
  </id_info>
  <brief_title>Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers</brief_title>
  <acronym>COCOA</acronym>
  <official_title>A Comparison of the Haemodynamic and Metabolic Effects of Intravenous Glucagon-like Peptide-1, Glucagon and Glucagon-like Peptide-1:Glucagon Co-agonism in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors,&#xD;
      GLP-1 and glucagon. Peptides will be intravenously infused, both in isolation, and&#xD;
      combination into healthy male participants. Overall, the aim of the study is to further our&#xD;
      understanding on the role these endogenous substances play (both in isolation and&#xD;
      combination) in haemodynamic regulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Co-agonist peptides (such as at the GLP-1:glucagon receptor) are currently in clinical&#xD;
      development for type 2 diabetes with the dual intention of reducing body weight and&#xD;
      controlling blood glucose. However, there is a lack of data on the effects that co-agonism&#xD;
      has on haemodynamic regulation.&#xD;
&#xD;
      Part A - Healthy male participants, by acting as their own control, will attend for five&#xD;
      intravenous infusion visits (combination of 0.9% saline, glucagon, GLP-1). These will occur&#xD;
      in a predefined but random order so that participants will be blinded to the infusion they&#xD;
      are receiving. Each infusion visit will comprise of 15 minute baseline followed by a 120&#xD;
      minute infusion. Detailed non-invasive cardiovascular measurements (including&#xD;
      peripheral/central blood pressure, heart rate, stroke volume, heart rate variability) and&#xD;
      bloods (including insulin, glucose, GLP-1, glucagon) will be collected as part of the study.&#xD;
&#xD;
      Part B - Healthy male participants, by acting as their own control, will attend for four&#xD;
      intravenous infusion visits (combination of 0.9% saline, glucagon, exenatide). These will&#xD;
      occur in a predefined but random order so that participants will be blinded to the infusion&#xD;
      they are receiving. Each infusion visit will comprise of 15 minute baseline followed by a 60&#xD;
      minute infusion. Detailed non-invasive cardiovascular measurements (including&#xD;
      peripheral/central blood pressure, heart rate, stroke volume, heart rate variability) and&#xD;
      bloods (including insulin, glucose, GLP-1, glucagon) will be collected as part of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A - 5 infusions Part B - 4 infusions</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Heart rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Brachial systolic and diastolic blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Central systolic and diastolic blood pressure and mean arterial pressure (mmHg) measured with SphygmoCor XCEL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Stroke volume (ml) measured by bioimpedance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Cardiac output (L/min) measured by bioimpedance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>peripheral vascular resistance (dynes/sec/cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Heart rate variability (normalised low frequency, LF, high frequency, HF and LF/HF ratio)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Glucose, in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>C-peptide, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Glucagon, in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Insulin, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Free fatty acids, in Î¼mol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Total GLP-1 and total active GLP-1, in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose homeostasis following intravenous infusion of 0.9% saline, glucagon, GLP-1, exenatide and their combination.</measure>
    <time_frame>Comparison between 2 hour infusion visit 1-5 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks</time_frame>
    <description>Gastric inhibitory polypeptide, in pg/ml</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Part A - Infusion A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 minute intravenous infusion of 0.9% saline&#xD;
Followed by:&#xD;
60 minute intravenous infusion of 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Infusion B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and 0.9% saline.&#xD;
Followed by:&#xD;
60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Infusion C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 minute intravenous infusion of glucagon 25ng/kg/min and 0.9% saline.&#xD;
Followed by:&#xD;
60 minute infusion of glucagon 50ng/kg/min and 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Infusion D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 25ng/kg/min.&#xD;
Followed by:&#xD;
60 minute infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 50ng/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Infusion E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 minute intravenous infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 25ng/kg/min.&#xD;
Followed by:&#xD;
60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 50ng/kg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Infusion A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 60 minute intravenous infusion of 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Infusion B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes followed by 25ng/min) and 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Infusion C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 60 minute intravenous infusion of glucagon (25ng/kg/min) and 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Infusion D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes then 25ng/min) and glucagon (25ng/kg/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>Intravenous infusion of 0.9% saline</description>
    <arm_group_label>Part A - Infusion A</arm_group_label>
    <arm_group_label>Part A - Infusion B</arm_group_label>
    <arm_group_label>Part A - Infusion C</arm_group_label>
    <arm_group_label>Part B - Infusion A</arm_group_label>
    <arm_group_label>Part B - Infusion B</arm_group_label>
    <arm_group_label>Part B - Infusion C</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 7-36 amide (0.6pmol/kg/min)</intervention_name>
    <description>Intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min</description>
    <arm_group_label>Part A - Infusion B</arm_group_label>
    <arm_group_label>Part A - Infusion D</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 7-36 amide (1.2pmol/kg/min)</intervention_name>
    <description>Intravenous infusion of GLP-1 7-36 amide 1.2pmol/kg/min</description>
    <arm_group_label>Part A - Infusion B</arm_group_label>
    <arm_group_label>Part A - Infusion E</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon (25ng/kg/min)</intervention_name>
    <description>Intravenous infusion of glucagon 25ng/kg/min</description>
    <arm_group_label>Part A - Infusion C</arm_group_label>
    <arm_group_label>Part A - Infusion D</arm_group_label>
    <arm_group_label>Part A - Infusion E</arm_group_label>
    <arm_group_label>Part B - Infusion C</arm_group_label>
    <arm_group_label>Part B - Infusion D</arm_group_label>
    <other_name>Glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon (50ng/kg/min)</intervention_name>
    <description>Intravenous infusion of glucagon 50ng/kg/min</description>
    <arm_group_label>Part A - Infusion C</arm_group_label>
    <arm_group_label>Part A - Infusion D</arm_group_label>
    <arm_group_label>Part A - Infusion E</arm_group_label>
    <other_name>Glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes</description>
    <arm_group_label>Part B - Infusion B</arm_group_label>
    <arm_group_label>Part B - Infusion D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to participate&#xD;
&#xD;
          -  Aged 18 to 40&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Current non-smoker&#xD;
&#xD;
          -  BMI &gt;18.0 and &lt;30kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Sustained Hypertension (sustained BP &gt;160/100mmHg) or hypotension (systolic BP below&#xD;
             90 mmHg)&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Implanted heart pace-maker or implantable cardioverter defibrillator (ICD)&#xD;
&#xD;
          -  Known active malignancy&#xD;
&#xD;
          -  Known renal failure (creatinine &gt;140Î¼mol/L)&#xD;
&#xD;
          -  Known diabetes mellitus (type 1 or 2)&#xD;
&#xD;
          -  Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits&#xD;
&#xD;
          -  Use of formal anticoagulant therapy such as, but not limited to, heparin, warfarin or&#xD;
             rivaroxaban&#xD;
&#xD;
          -  Current involvement in the active treatment phase of other research studies,&#xD;
             (excluding observations/noninterventional)&#xD;
&#xD;
          -  Any other clinical reason which may preclude entry in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Wilkinson, MA DM FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Goodman, MD</last_name>
    <phone>01223 336806</phone>
    <phone_ext>+44</phone_ext>
    <email>jdhg3@medschl.cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Goodman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Ian B Wilkinson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

